Incyte's Jakafi 1st drug OK'd in polycythemia vera

One day ahead of its Prescription Drug User Fee Act action date, Incyte's oral JAK1/JAK2 inhibitor Jakafi (ruxolitinib) won the FDA's approval in patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea – the first drug to gain that indication in the US.

One day ahead of its Prescription Drug User Fee Act action date, Incyte's oral JAK1/JAK2 inhibitor Jakafi (ruxolitinib) won the FDA's approval in patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea – the first drug to gain that indication in the US.

PV, which affects about 100,000 Americans, is a myeloproliferative neoplasm (MPN) characterized by an overproduction of normal red-blood cells, white-blood...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category